Table 5 B/I activated tDLN track preferentially to 4T1 tDLN and persist
Tumor | Â | MethA | 4T1 | No Tumor |
|---|---|---|---|---|
Day 3 | Spleen | 2.1% | 10.4% | 2.4% |
Day 6 | Spleen | 0.5% | 3.3% | 1.7% |
Day 3 | tDLN | 3.1% | 9.2% | _____ |
Day 6 | tDLN | 2% | 10.1% | _____ |
Tumor | Â | MethA | 4T1 | No Tumor |
|---|---|---|---|---|
Day 3 | Spleen | 2.1% | 10.4% | 2.4% |
Day 6 | Spleen | 0.5% | 3.3% | 1.7% |
Day 3 | tDLN | 3.1% | 9.2% | _____ |
Day 6 | tDLN | 2% | 10.1% | _____ |